Thrombolysis: the need for a critical review

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• The Thrombolysis in Myocardial Infarction (TIMI)-I trial suggested recombinant tissue-type plasminogen activator (rt-PA) would outperform streptokinase in acute myocardial infarction (AMI).
• This hypothesis posited that rt-PA's higher reperfusion rates would translate to reduced infarct size and mortality.

Discussion:

• Numerous subsequent trials, including TIMI-I, European Cooperative Study Group, PAIMS, GISSI-2, and ISIS-3, failed to substantiate the initial hypothesis.
• Comparisons involving rt-PA against streptokinase, and also against anisoylated plasminogen-streptokinase activator complex (APSAC/anistreplase), did not confirm the expected benefits.
• The abstract suggests a deviation from the scientific method, where studies were rejected instead of the unconfirmed hypothesis.

Key Insights:

• Extensive clinical evidence does not support the hypothesis that rt-PA offers superior outcomes in AMI compared to older thrombolytic agents.
• The failure to confirm the hypothesis across multiple large-scale trials highlights potential biases or flaws in the initial interpretation of TIMI-I results.
• A lack of independent review may have perpetuated the unconfirmed hypothesis.

Outlook:

• There is a critical need for adherence to rigorous scientific review standards, ensuring critical distance and independence.
• Promoting independent scientific inquiry, review, and debate is essential for accurate interpretation of clinical trial data.
• Future research and interpretation of therapeutic interventions in cardiology must prioritize objective evidence over pre-existing hypotheses.